Prorenin receptor blockers may offer superior protection against end-organ damage in diabetes and hypertension compared to conventional RAS inhibitors by targeting both RAS-dependent and independent pathways.
No takes yet. Share an insight, caveat, or question.
Should not yet change RAS inhibitor practice in diabetes or hypertension; leaves open need for outcome trials of prorenin receptor blockade.
Ichihara et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: